Duloxetine Capsule, Delayed Release
Product Images NDC 27241-099

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 27241-099). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine 20mg

This text describes the details of Duloxetine Hydrochloride USP, its dosage, storage, and other instructions. It also mentions the manufacturer, dosage guide, and precautions such as keeping it out of children's reach and not using it if the inner seal is missing or broken. The medicine comes in the form of 60 capsules containing enteric-coated pellets equivalent to 22.4 mg of Duloxetine Hydrochloride USP for treating depression, anxiety, and pain in adults. The test for the USP assay and organic impurities is pending.*

FDA Label Image

Duloxetine 30mg

The text describes the contents of each capsule containing Duloxetine Hydrochloride USP equivalent to 30 mg Duloxetine. It advises dispensing in a tightly closed container and provides instructions for storage in a controlled temperature environment. Usage guidelines are not provided clearly, and the USP assay and Organic Impurities test are still pending. The medication guide should be provided to each patient. The text also includes other relevant details such as manufacturer and product code but does not provide any accompanying literature for dosage.*

FDA Label Image

Duloxetine 40mg

This is a description of Duloxetine Hydrochloride USP, a medication capsule manufactured and marketed by Ajanta Pharma Limited. Each capsule contains 4.9 mg of Duloxetine Hydrochloride USP, an equivalent dosage of 40 mg Duloxetine, and is coated to prevent gastric irritation. The dosage guidelines are available in the accompanying literature and should be kept in a tightly closed container, out of reach of children. The capsules are currently undergoing USP Assay & Organic Impurities testing. They can be stored in temperatures ranging from 15° to 30°C (59° to 86°F). The product is sold in a package of 30 capsules with an NDC code of 27241-164-30.*

FDA Label Image

Duloxetine 60mg

Duloxetine is available in the form of enteric-coated pellets of 67.3 mg which is equivalent to 60 mg Duloxetine Hydrochloride USP. The usual dose and other information are available in the accompanying literature. It should be kept in a tightly closed container and out of reach of children. USP Assay & Organic Impurities test is pending. It should be stored between 15°C to 30°C. It should not be used if the inner seal is missing or broken. The medication is marketed by Ajanta Pharma USA Inc. with the code No. MH/DRUGS/AD/018 and NDC 27241-099-03. It is made in India. The pharmacist should dispense the accompanying medication guide to each patient.*

FDA Label Image

Duloxetine Fig1

FDA Label Image

Duloxetine Fig10

FDA Label Image

Duloxetine Fig2

This is a graphical representation of the proportion of patients with relapse for placebo and duloxetine treatments over a period of time after randomization. The x-axis shows the time from randomization to relapse in days and the y-axis represents the proportion of patients with relapse. The graph shows a comparison between the two treatments: placebo and duloxetine. The proportion of patients with relapse for both treatments is indicated by the different lines.*

FDA Label Image

Duloxetine Fig3

The text seems to be a table showing the percentage of patients who improved after taking Duloxetine 60mg twice a day, Duloxetine 60mg once a day, Duloxetine 20mg once a day, and Placebo. Additionally, the table displays the percentage improvement in pain from baseline.*

FDA Label Image

Duloxetine Fig4

FDA Label Image

Duloxetine Fig5

This is a graph that compares the percentage of patients who showed improvement in their pain after taking either Duloxetine 60mg twice daily or Duloxetine 60mg once daily or a placebo. The graph shows that the group who took Duloxetine 60mg twice daily had the highest percentage of improvement, followed by the group who took Duloxetine 60mg once daily, and lastly, the placebo group showing the least percentage of improvement.*

FDA Label Image

Duloxetine Fig6

FDA Label Image

Duloxetine Fig8

The text describes a medical treatment for pain management using Duloxetine at 60/120 mg once per day. There is a chart indicating the percentage of improvement in pain from a baseline measurement. The rest of the text appears to include random characters and does not provide any additional meaningful information.*

FDA Label Image

Duloxetine Fig9

This is a description of a clinical trial that studied the effect of Duloxetine 60 mg once daily on pain improvement compared to a placebo. The chart shows the percentage improvement in pain from baseline in patients taking Duloxetine compared to those taking a placebo. However, due to the poor quality of the text, some characters are not recognizable or not in English, making the text difficult to read and understand.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.